We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Caprion Proteomics and Applied Biosystems Work Together to Accelerate Protein Biomarker Verification and Validation
News

Caprion Proteomics and Applied Biosystems Work Together to Accelerate Protein Biomarker Verification and Validation

Caprion Proteomics and Applied Biosystems Work Together to Accelerate Protein Biomarker Verification and Validation
News

Caprion Proteomics and Applied Biosystems Work Together to Accelerate Protein Biomarker Verification and Validation

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Caprion Proteomics and Applied Biosystems Work Together to Accelerate Protein Biomarker Verification and Validation"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Caprion Proteomics Inc. has announced that it is working with Applied Biosystems, a division of Life Technologies Corporation, to accelerate the verification and validation of protein biomarker candidates toward potential use in clinical settings.

Caprion is extending its leadership in mass spectrometry-based biomarker services, by applying QTRAP technology for the development and deployment of multiple reaction monitoring (MRM) assays to advance the clinical validation of biomarker candidates. Caprion will discuss this scientific initiative at the Biomarker World Congress 2009 conference in Philadelphia.

Discovery of a significant number of biomarker candidates in academia and industry has created the need to verify and validate these markers in large-scale projects, to determine the most promising for clinical development. Caprion specializes in large-scale studies of biomarkers as a service for pharmaceutical and biotechnology companies, as well as for government agencies. Applied Biosystems provides mass spectrometry technology that complements Caprion’s long-standing strength in biomarker discovery, to address the need to advance candidates along the biomarker continuum.

QTRAP technology, which was developed by the Applied Biosystems/MDS Analytical Technologies joint venture, enables integrated quantitative and qualitative analysis through the MIDAS workflow, for MRM assay development and quantitative results. This makes it the technology of choice for Caprion to expand its quantitative capabilities into this rapidly emerging field.
Advertisement